Esperion Therapeutics (ESPR) Earnings Analysis
Esperion Therapeutics (ESPR) has no confirmed upcoming earnings date. Last quarter (2026-05-08) it missed with EPS -0.1 USD vs -0.04 USD est (-150%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -131.40.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ESPR next report earnings?
No confirmed upcoming earnings date is currently scheduled for ESPR. This page updates as the calendar is published.
ESPR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-08 | -0.1 USD | -0.04 USD | -150% | Miss |
| 2026-03-10 | 0.22 USD | 0.23 USD | -4.3% | Miss |
| 2025-11-06 | -0.16 USD | -0.09 USD | -77.8% | Miss |
| 2025-03-04 | -0.1 USD | -0.14 USD | +28.6% | Beat |
| 2024-11-07 | -0.15 USD | -0.14 USD | -7.1% | Miss |
| 2024-08-12 | -0.05 USD | -0.15 USD | +66.7% | Beat |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
ESPR valuation and analyst view
| Trailing P/E | -131.40 |
|---|---|
| Trailing EPS | -0.02953 USD |
| Price / book | -2.60 |
| Dividend yield | 99.37% |
| Market cap | 0.66B |
| Analyst consensus | Hold (8 buy / 15 hold / 2 sell) |
| Avg price target | 3.19 USD |
Related research pages
Frequently asked questions
When is Esperion Therapeutics (ESPR)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ESPR. This page updates as the calendar is published.
Did ESPR beat earnings last quarter?
In its 2026-05-08 report, ESPR posted EPS of -0.1 USD versus a -0.04 USD estimate — a miss of 150%.
What is ESPR's earnings track record?
Over the last 6 reported quarters with consensus data, ESPR beat estimates 2 times (33%).
What is ESPR's current P/E ratio and EPS?
ESPR trades at a trailing P/E of -131.40 on trailing EPS of -0.029532161781375542 USD.
What do analysts rate ESPR?
Analyst consensus is "Hold" across 25 ratings (0 strong buy, 8 buy, 15 hold, 2 sell, 0 strong sell). Average 12-month price target: 3.19 USD.